Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin.

Literature DB >> 12138903

Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin.

Yasunobu Abe¹, Shinji Yashiki, Ilseung Choi, Keiichi Hara, Takamitsu Matsushima, Junji Nishimura, Shoichi Inaba, Hajime Nawata, Koichiro Muta.

Abstract

We describe the case of a 55-year-old man with adult T-cell leukemia/lymphoma (ATL) in first remission who underwent nonmyeloablative allogeneic peripheral blood stem cell transplantation with conditioning consisting of 4 courses of pentostatin and low-dose total body irradiation. Complete chimerism in peripheral blood was achieved on day 42 without severe myelosuppression. Concomitantly, the proviral DNA load for human T-cell leukemia virus I (HTLV-I) in peripheral blood mononuclear cells decreased below detectable limits and was still undetectable on day 270. This fact indicates that eradication of ATL cells is feasible by induction of an alloimmune response without high-dose chemoradiotherapy.

Entities: Chemical Disease Species

Mesh：

Substances：
Pentostatin

Year: 2002 PMID： 12138903 DOI： 10.1007/bf02982725

Source DB: PubMed Journal: Int J Hematol ISSN： 0925-5710 Impact factor: 2.490

13 in total

1. Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia.

Authors: K Obama; M Tara; H Sao; H Taji; Y Morishima; H Mougi; Y Maruyama; M Osame
Journal: Int J Hematol Date: 1999-04 Impact factor: 2.490

2. Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients.

Authors: R G Steis; W J Urba; W C Kopp; W G Alvord; J W Smith; D L Longo
Journal: J Natl Cancer Inst Date: 1991-11-20 Impact factor: 13.506

3. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation.

Authors: R Sobue; T Yamauchim; K Miyamura; H Sao; T Tahara; H Yoshikawa; S Yoshikawa; Y Morishima; Y Kodera
Journal: Bone Marrow Transplant Date: 1987-12 Impact factor: 5.483

4. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.

Authors: I F Khouri; R M Saliba; S A Giralt; M S Lee; G J Okoroji; F B Hagemeister; M Korbling; A Younes; C Ippoliti; J L Gajewski; P McLaughlin; P Anderlini; M L Donato; F F Cabanillas; R E Champlin
Journal: Blood Date: 2001-12-15 Impact factor: 22.113

5. Real-time polymerase chain reaction for quantification of HTLV-1 proviral load: application for analyzing aberrant integration of the proviral DNA in adult T-cell leukemia.

Authors: S Kamihira; N Dateki; K Sugahara; Y Yamada; M Tomonaga; T Maeda; M Tahara
Journal: Int J Hematol Date: 2000-07 Impact factor: 2.490

6. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T cells from a donor immunized with human T-cell leukemia virus type 1 Tax-coding DNA vaccine.

Authors: T Ohashi; S Hanabuchi; H Kato; H Tateno; F Takemura; T Tsukahara; Y Koya; A Hasegawa; T Masuda; M Kannagi
Journal: J Virol Date: 2000-10 Impact factor: 5.103

7. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection.

Authors: C Thiede; M Florek; M Bornhäuser; M Ritter; B Mohr; C Brendel; G Ehninger; A Neubauer
Journal: Bone Marrow Transplant Date: 1999-05 Impact factor: 5.483

8. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease.

Authors: S Jacobson; H Shida; D E McFarlin; A S Fauci; S Koenig
Journal: Nature Date: 1990-11-15 Impact factor: 49.962

9. Cytotoxic T cell response and expression of the target antigen in HTLV-I infection.

Authors: M Kannagi; S Matsushita; H Shida; S Harada
Journal: Leukemia Date: 1994-04 Impact factor: 11.528

10. 2'-Deoxycoformycin therapy in adult T-cell leukemia/lymphoma.

Authors: W Lofters; M Campbell; W N Gibbs; B D Cheson
Journal: Cancer Date: 1987-12-01 Impact factor: 6.860

7 in total

1. Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109).

Authors: Kunihiro Tsukasaki; Kensei Tobinai; Masanori Shimoyama; Mitsuo Kozuru; Naokuni Uike; Yasuaki Yamada; Masao Tomonaga; Koichi Araki; Masaharu Kasai; Kiyoshi Takatsuki; Mitsutoshi Tara; Chikara Mikuni; Tomomitsu Hotta
Journal: Int J Hematol Date: 2003-02 Impact factor: 2.490

Review 2. Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma.

Authors: Jun Okamura; Naokuni Uike; Atae Utsunomiya; Ryuji Tanosaki
Journal: Int J Hematol Date: 2007-08 Impact factor: 2.490

3. Durable hematologic complete response and suppression of HTLV-1 viral load following alemtuzumab in zidovudine/IFN-{alpha}-refractory adult T-cell leukemia.

Authors: Andrew Mone; Shannon Puhalla; Susan Whitman; Robert A Baiocchi; Julio Cruz; Tamara Vukosavljevic; Amy Banks; Charles F Eisenbeis; John C Byrd; Michael A Caligiuri; Pierluigi Porcu
Journal: Blood Date: 2005-08-02 Impact factor: 22.113

4. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.

Authors: Kensei Tobinai; Naokuni Uike; Yoshio Saburi; Takaaki Chou; Tetsuya Etoh; Masato Masuda; Fumio Kawano; Masao Matsuoka; Hirokuni Taguchi; Torahiko Makino; Yoshinobu Asano; Kazuo Tamura; Yasuo Ohashi
Journal: Int J Hematol Date: 2003-06 Impact factor: 2.490